Abstract:Chimeric antigen receptor (CAR) T cells are revolutionizing cancer therapy, particularly for haematological malignancies, conferring durable and sometimes curative responses in patients with advanced-stage disease. The CAR T cell products currently approved for clinical use are all autologous and are often effective; however, in patients who are lymphopenic and/or heavily pretreated with chemotherapy, autologous T cells can be difficult to harvest in sufficient numbers or have functional impairments that might ultimately render them less efficacious. Moreover, autologous products take several weeks to produce, and each product can be used in only one patient. By contrast, allogeneic CAR T cells can be produced for many patients using T cells from a single healthy donor, can be optimized for safety and efficacy, can be instantly available for 'off-the-shelf' use and, therefore, might also be more cost-effective. Despite these potential advantages, the development of allogeneic CAR T cells has lagged behind that of autologous products, owing to the additional challenges such as avoiding graft-versus-host disease and host-mediated graft rejection. Over the past few years, the development of advanced genome-editing techniques has facilitated the generation of novel allogeneic CAR T cell products. Furthermore, CAR cell products derived from other cell types such as induced pluripotent stem cells and natural killer cells are being investigated for clinical use. In this Review, we discuss the potential of allogeneic CAR cell products to expand life-saving immunotherapy to a much broader population of patients in the coming years, the progress made to date and strategies to overcome remaining hurdles.

Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases

The Future of CAR T Therapeutics to Treat Autoimmune Disorders

CAR T cells for treating autoimmune diseases

Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus

Toward “off‐the‐shelf” allogeneic CAR T cells

Application and research progress of CAR-T cell therapy in autoimmune diseases

Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections

Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease

Chimeric antigen receptor T-cell therapy in autoimmune diseases

Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks

Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models

Chimeric antigen receptor T cell therapy for autoimmune disease

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Allogeneic "Off-the-Shelf" CAR T cells: Challenges and advances

Engineering CAR-T therapies for autoimmune disease and beyond

Chimeric antigen receptor T cells in the fast lane among autoimmune disease therapies

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

Tuning the performance of CAR T cell immunotherapies

CAR T cells in autoimmune disease: On the road to remission

Off-the-shelf CAR-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting

CAR-engineered T cell therapy as an emerging strategy for treating autoimmune diseases